Market Newsdesk

New Amplitude Partner Ecosystem helps customers accelerate the business impact of digital product innovation

Emerald Organic Products Inc. (d/b/a Healixa Inc.) Announces Further Execution of its PHASE I National Pharmacy Business Rollout

Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
[email protected]

The Sonic Fund II, L.P. Issues Presentation Correcting Adverum’s Misstatements

Highlights Numerous Mischaracterizations in Adverum’s Recent Investor Presentation

Sonic’s Sole Aim in this Contest is for Adverum to Have Best Board Possible to Ensure Development and Approval of Company’s Potentially Life-Changing Treatment

Urges Stockholders to Vote on the GREEN Proxy Card Today to Elect Sonic’s Three Independent Director Nominees to Drastically Improve Board

HONOLULU–(BUSINESS WIRE)–
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued a supplemental presentation detailing – and correcting – a number of the Company’s recent misstatements. Sonic has nominated three independent, highly qualified director candidates – Jean Bennett, Jodi Cook and Herbert Hughes (the “Nominees”) – for election to the Adverum Board of Directors (the “Board”) at the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”).

The presentation, entitled “Adverum’s Myths: Correcting the Record,” is available at: https://www.saveadverum.com/investor-materials.

Vote on the GREEN proxy card today

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005486/en/

Investors:

Saratoga Proxy Consulting LLC

John Ferguson / Ann Marie Mellone 212-257-1311

[email protected] / [email protected]

Media:

Sloane & Company

Joe Germani / Sarah Braunstein

[email protected] / [email protected]

KEYWORDS: Hawaii United States North America

INDUSTRY KEYWORDS: Biotechnology Professional Services Health Finance

MEDIA:

Logo

GlycoMimetics to Report First Quarter Financial Results on May 3, 2021

ROCKVILLE, Md.–(BUSINESS WIRE)–
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 9891637. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able to connect.

A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 9891637.

About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005438/en/

Investor Contact:

Shari Annes

Phone: 650-888-0902

Email: [email protected]

Media Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email: [email protected]

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Biotechnology General Health Health Pharmaceutical Oncology

MEDIA:

Logo

Bank of America Announces $1.5 Million Commitment to Advance Racial Equality and Economic Opportunity in Massachusetts

BOSTON–(BUSINESS WIRE)–
Bank of America today announced a $1.5 million commitment as part of its work to advance racial equality and economic opportunity in Massachusetts. King Boston, an organization dedicated to raising awareness of the legacy of Dr. Martin Luther King Jr. and Coretta Scott King in Boston, and the Massachusetts League of Community Health Centers, which offers support and assistance to the state’s 52 community health centers, will both receive funding. The grant funding is aligned to the bank’s $1.25 billion, five-year commitment, which further accelerates work already underway to address racial inequality and catalyze similar efforts across the private sector.

King Boston, founded in 2017 to create a memorial and related programming honoring Dr. Martin Luther King Jr. and Coretta Scott King’s legacy, will receive a $1 million grant from Bank of America. The grant will support: the creation of the memorial, named The Embrace, on the Boston Common; a new Center for Economic Justice in Nubian Square to promote solutions to further racial and economic justice; and a public ideas series that engages the community in anti-racist discourse through the arts and humanities.

“It is with generous contributions from large, established institutions that we are able to interrogate racism and advocate for the issues that Dr. and Mrs. King fought for over 50 years ago – wealth, housing, racial equity and public education,” said Imari Paris Jeffries, executive director of King Boston. “Thanks to our corporate partners like Bank of America for investing in change, and for their ongoing commitment to everything King Boston represents – convening, learning, healing, appreciating and honoring.”

The Massachusetts League of Community Health Centers, which together serves more than one million people across the state, has been awarded a $500,000 grant from Bank of America to address critical health equity concerns with COVID-19 vaccine distribution. The state’s community health centers are uniquely positioned in communities of color to address these gaps as the vaccine rollout expands and accelerates.

“Bank of America’s generous contribution recognizes the need for both an urgent infusion of funds and support for building longer-term responses to inequities. Immediate funding will go far in helping us meet expanding demand for the COVID-19 vaccine in the communities we serve – the same communities that have been unduly battered by the pandemic,” said Michael Curry, President & CEO of the Massachusetts League of Community Health Centers. “At the same time, the flexibility of this funding will give us room to respond to community-specific needs and support social, health and economic recovery as we work our way out of this pandemic.”

“The health and humanitarian crisis has demonstrated just how far we have to go in correcting longstanding inequities in our society,” said Miceal Chamberlain, President of Bank of America Massachusetts. “The time for action is upon us and our hope is that by continuing to take specific steps to address economic and racial disparities, we can serve as a catalyst for a broader response across the private sector.”

To date, the bank has made more than $350 million in various investments from its initial $1 billion commitment, announced in June 2020, across the primary focus areas of health, jobs/reskilling, affordable housing and small business, including providing support to Pine Street Inn, Innovation Studio, Morgan Memorial Goodwill Industries, La Colaborativa and Asian American Civic Association locally in Boston.

About Bank of America

At Bank of America, we’re guided by a common purpose to help make financial lives better, through the power of every connection. We’re delivering on this through responsible growth with a focus on our environmental, social and governance (ESG) leadership. ESG is embedded across our eight lines of business and reflects how we help fuel the global economy, build trust and credibility, and represent a company that people want to work for, invest in and do business with. It’s demonstrated in the inclusive and supportive workplace we create for our employees, the responsible products and services we offer our clients, and the impact we make around the world in helping local economies thrive. An important part of this work is forming strong partnerships with nonprofits and advocacy groups, such as community, consumer and environmental organizations, to bring together our collective networks and expertise to achieve greater impact. Learn more at about.bankofamerica.com, and connect with us on Twitter (@BofA_News).

For more Bank of America news, including dividend announcements and other important information, visit the Bank of America newsroom and register for news email alerts.

www.bankofamerica.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005475/en/

Reporters may contact:

Carla Molina, Bank of America

[email protected]

832.283.2681 

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Banking Fund Raising Foundation Professional Services Philanthropy

MEDIA:

Logo

Curtiss-Wright to Host Virtual Investor Day on May 26, 2021

DAVIDSON, N.C.–(BUSINESS WIRE)–
Curtiss-Wright Corporation (NYSE: CW) today announced that it will host a Virtual Investor Day on Wednesday, May 26, 2021 from 8:30 a.m. EDT to approximately 11:30 a.m. EDT.

The event will include presentations from members of Curtiss-Wright’s senior management team including Lynn M. Bamford, President and Chief Executive Officer, K. Christopher Farkas, Vice President and Chief Financial Officer, and Kevin M. Rayment, Vice President and Chief Operating Officer, as well as other executives, and will be followed by a question and answer session. The agenda will include the Company’s strategy for long-term profitable growth and the introduction of new long-term financial targets.

A live webcast of the presentations and question and answer session will be available through the Company’s Investor Relations section of Curtiss-Wright’s website at investors.curtisswright.com. Registration for the event is encouraged and can be completed in advance on the Investor Day 2021 Registration Site.

An archived replay of the webcast and slides shown during the presentations will be available following the completion of the event for one year.

About Curtiss-Wright Corporation

Curtiss-Wright Corporation (NYSE:CW) is a global innovative company that delivers highly engineered, critical function products and services to the Aerospace and Defense markets, and to the Commercial markets including Power, Process and General Industrial. Building on the heritage of Glenn Curtiss and the Wright brothers, Curtiss-Wright has a long tradition of providing reliable solutions through trusted customer relationships. The company employs approximately 8,200 people worldwide. For more information, visitwww.curtisswright.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005471/en/

Jim Ryan

(704) 869-4621

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Other Defense Other Energy Hardware Energy Technology Defense Engineering Air Transport Aerospace Other Technology Manufacturing

MEDIA:

Logo

Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome

– Methods of use patent expected to provide patent protection through 2040.

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application No. 16/994,368. The allowed patent application covers methods of treating Alagille syndrome using maralixibat, an investigational treatment being evaluated for patients with Alagille syndrome, a rare and life-threatening cholestatic liver disease. The patent application is expected to issue in 2021 and will provide patent protection in the United States of the claimed methods of use of maralixibat into 2040.

Mirum has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. In March 2021, the NDA was accepted for priority review by the FDA and issued a PDUFA date of September 29, 2021. Maralixibat is also being evaluated in clinical studies for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, both of which are also cholestatic liver diseases.

A notice of allowance is a written notification issued after the USPTO makes a determination that a patent can be granted from an application. The majority of patent applications that receive a notice of allowance will proceed to issue as a U.S. patent. However, a notice of allowance is not a guarantee of patent issuance.

About Maralixibat

Maralixibat is a novel, minimally absorbed, orally administered investigational drug being evaluated in several rare cholestatic liver diseases. Maralixibat inhibits the apical sodium dependent bile acid transporter (ASBT), resulting in more bile acids being excreted in the feces, leading to lower levels of bile acids systemically, thereby potentially reducing bile acid mediated liver damage and related effects and complications. More than 1,600 individuals have received maralixibat, including more than 120 children who have received maralixibat as an investigational treatment for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). In the ICONIC Phase 2b ALGS clinical trial, patients taking maralixibat had significant reductions in bile acids and pruritus compared to placebo, as well as reduction in xanthomas and accelerated growth long-term. In a Phase 2 PFIC study, a genetically defined subset of BSEP deficient (PFIC2), patients responded to maralixibat with an increase in transplant-free survival. The U.S. Food and Drug Administration has granted maralixibat Breakthrough Therapy designation for the treatment of pruritus associated with ALGS in patients one year of age and older and for PFIC2. Maralixibat was generally well-tolerated throughout the studies. The most frequent treatment-related adverse events were diarrhea and abdominal pain. Until maralixibat is approved and available for prescribing, the medication is available to patients with ALGS through Mirum’s expanded access program. For more information, please visit ALGSEAP.com. For more information about the Phase 3 study for maralixibat in pediatric patients with PFIC, visit PFICtrial.com.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency. Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis. For more information, visit MirumPharma.com.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize two gene therapy programs, VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics, following preclinical evaluation and IND/CTA-enabling studies.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the date Mirum’s patent application is expected to issue and the duration of such patent protection in the United States. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “expects,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005266/en/

Media:

Erin Murphy

[email protected]

Investors:

Ian Clements, Ph.D.

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo

First American Awarded 30^th U.S. Patent, Further Demonstrating Its Leadership in Title and Settlement Innovation

—Patent for artificial intelligence-driven enhancement to optical character recognition is the latest in the company’s portfolio of patents spanning automated title underwriting and production, mortgage loan risk assessment, and data extraction—

SANTA ANA, Calif.–(BUSINESS WIRE)–First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today announced that the United States Patent and Trademark Office has issued the company a patent for an innovative improvement to optical character recognition (OCR) technology that leverages artificial intelligence. The patented enhancement applies artificial intelligence to rapidly, efficiently, and accurately validate and correct text obtained from a document image via OCR, fueling more accurate automated title underwriting and production on key text-based components of the title policy.

“The new patent for OCR Error Correction is the eighth patent we have been awarded in the last 12 months and further demonstrates First American’s continuing leadership in driving innovation within the title and settlement services industry,” said Dennis J. Gilmore, CEO, First American Financial Corporation. “First American has been at the forefront of title and settlement innovation for decades, leading the industry shift to computer-based title plants in the late 20^th century, and continues to drive innovation today, leveraging artificial intelligence and machine learning technologies to accelerate the digital transformation of the real estate settlement process.”

The U.S. Patent No. 10,896,292 titled “OCR Error Correction” is the 30^th active patent in First American’s portfolio, which includes:

• Patents on technologies that facilitate the automated underwriting and production of title insurance;
• Patents on technologies that enable risk assessments of mortgage loans;
• Patents on technologies that improve the speed and precision of data collection or extraction from source documents, including documents essential to the underwriting of title insurance policies;
• Patents related to optical character recognition technologies that help to unlock and structure the data held in millions of public records, powering automated title production breakthroughs, as well as enhancing the breadth and accuracy of title plant data.

The company also has an additional 12 patent applications pending that include technologies that will further advance First American’s efforts to transform the title and settlement services industry.

The latest patent reflects First American’s commitment to invest in technologies that support automated title production and to the application of new technologies to title and settlement processes.

“Automated title production and accelerating the digital transformation of real estate transactions depend upon obtaining accurate, structured data from document images. This patented method allows us to transform unstructured data pulled from public records and other sources into structured data more rapidly and with greater accuracy than conventional OCR validation and error correction techniques,” said Mark Fleming, senior vice president of Decision Sciences at First American. “This patent builds on our rich history of innovation, including pioneering a variety of OCR technology advancements and other data extraction techniques that help move our automated title underwriting and production efforts forward.”

About First American

First American Financial Corporation (NYSE: FAF) is a leading provider of title insurance, settlement services and risk solutions for real estate transactions that traces its heritage back to 1889. First American also provides title plant management services; title and other real property records and images; valuation products and services; home warranty products; banking, trust and wealth management services; and other related products and services. With total revenue of $7.1 billion in 2020, the company offers its products and services directly and through its agents throughout the United States and abroad. In 2021, First American was named to the Fortune 100 Best Companies to Work For^® list for the sixth consecutive year. More information about the company can be found at www.firstam.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005299/en/

Media Contact:

Marcus Ginnaty

Corporate Communications

First American Financial Corporation

(714) 250-3298

Investor Contact:

Craig Barberio

Investor Relations

First American Financial Corporation

(714) 250-5214

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Residential Building & Real Estate Insurance Commercial Building & Real Estate Finance Construction & Property Banking

MEDIA:

Logo